Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 127Kidney Neoplasms 39Neoplasms 37Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 27Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Stomach Neoplasms 8Neuroendocrine Tumors 8Carcinoma 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Adenoma, Islet Cell 6Uveal Melanoma 5

Interventions

masitinib 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastro Intestinal Stromal Tumor × Sunitinib × Clear all
NCT01506336 2018-12-11

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

AB Science

Phase 2 Completed
44 enrolled

Gastro Intestinal Stromal Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡